- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00555555
제3형 Von Willebrand 환자에서 Alphanate FVIII/VWF 농축액의 효능
선천성 제3형 폰빌레브란트병 환자의 수술 중 과도한 출혈을 예방하는 FVIII/VWF 복합체(인간), Alphanate®의 효능 및 안전성을 평가하기 위한 시판 후 관찰 연구
To assess the efficacy of FVIII/VWF Complex (Human), Alphanate® as replacement therapy in preventing excessive bleeding in subjects with congenital Type 3 von Willebrand Disease (VWD) who undergo surgical procedures.
연구 개요
상세 설명
For the treatment of surgical procedures the intended dose of Alphanate® will be given as a single dose or as multiple doses over several days, depending on the clinical situation, and according to the Full Prescribing Information guideline and the investigator's judgment. For each treated event, the subject's treatment period will be finished when, in the opinion of the local Investigator, the participating subject would not benefit from further infusions of the study concentrate.
연구 유형
등록 (실제)
단계
- 4단계
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Male or female 7 years of age or older
- The subject has been diagnosed of inherited VWD of Type 3 as determined by subject's medical records.
- The subject needs a surgical procedure (at least 10 surgical procedures have to be considered as "Major" according to the criteria of the protocol).
- The subject is expected to respond to exogenously administered FVIII/VWF according to Investigator's judgment.
- The subject freely gives written informed consent. Subjects who are not legally permitted to provide written consent must sign a form of assent for study participation, and written consent must be provided by a parent or legal guardian.
Exclusion Criteria:
- The subject has been diagnosed of Type 1, Type 2, or acquired VWD.
- The subject is known to have history of intolerance to any Alphanate® containing substance.
- The subject is known to have history of anaphylactic reaction(s) to blood or blood components.
- Liver function tests (AST, ALT, bilirubin) > 2.5 x upper limit of normal (ULN).
- Renal function test (creatinine) > 1.5 x ULN.
- The subject is known or suspected to have present or past inhibitor activity (antibodies) directed against FVIII or VWF.
- The subject is known to abuse alcohol or illicit drug use within the past 12 months.
- The subject is participating in another clinical study involving an investigational treatment, or participated within the past 4 weeks. Studies consisting of data and blood sampling collections on a regular or long-term basis are exempt from this exclusion.
- The subject is unlikely to adhere to the protocol requirements of the study.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Coagulation FVIII/VWF
Anti-Hemophilic/von Willebrand Factor VIII (Human) Alphanate SD/HT |
A general guideline based on the product Full Prescribing Information is recommended with a maximum dose of 80 VWF:RCof IU/kg. The number of administrations before, during, and after the surgery procedure depends on the subject's clinical condition and the type of surgery itself. Single administrations or multiple doses may be appropriate. The dose of Alphanate® administered to each subject will be recorded as IU of VWF:RCof and also as IU of FVIII:C. The lot number for each vial of concentrate administered will also be recorded.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Investigator Overall Rating as a Measure of the Overall Treatment Outcome for Each Treated Surgical Procedure
기간: Up to 30 days
|
The local Investigator to rate the replacement treatment outcome (Investigator Overall Rating - Verbal Rating Scale) as a measure of overall clinical efficacy for each treated event. It is rated using a 2-point Verbal Rating Scale as: Excellent/Good and Poor/None. |
Up to 30 days
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Number of Surgical Procedures at Both Visits Rated as Excellent/Good by the Investigator
기간: Day 0 (surgery day) and Day 1 (post-surgery day)
|
The number of surgical procedures rated by the local Investigator for the treatment outcomes at both visits. |
Day 0 (surgery day) and Day 1 (post-surgery day)
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Sandra Camprubi, Instituto Grifols, S.A.
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정된)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- GBI0703
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .